Showing results (261-270 of 653) with videos related to

Sort By:
Pageof 66
Surgical Endoscopy|January 5, 2021
The significance of the time to arterial perfusion in intraoperative ICG angiography during colorectal surgeryToshisada Aiba, Kay Uehara, Atsushi Ogura, et al.
World Journal of Surgery|October 5, 2022
Controlling Nutritional Status Score Serves as a Prognosticator in Esophageal Squamous Cell Carcinoma: Optimal Timing of Evaluation of Patients Undergoing Neoadjuvant TreatmentIkue Nonogaki, Mitsuro Kanda, Dai Shimizu, et al.
Annals of Surgical Oncology|October 13, 2019
Modified Systemic Inflammation Score is Useful for Risk Stratification After Radical Resection of Squamous Cell Carcinoma of the EsophagusMitsuro Kanda, Masahiko Koike, Chie Tanaka, et al.
Surgery Today|January 30, 2015
Optimal Roux-en-Y reconstruction after distal gastrectomy for early gastric cancer as assessed using the newly developed PGSAS-45 scaleHiroshi Kawahira, Yasuhiro Kodera, Naoki Hiki, et al.
Journal of Surgical Oncology|July 1, 2014
Epithelial to mesenchymal transition correlates with tumor budding and predicts prognosis in esophageal squamous cell carcinomaYukiko Niwa, Suguru Yamada, Masahiko Koike, et al.
Annals of Surgical Oncology|March 13, 2025
Association of NR0B1 with Malignant Phenotypes in Esophageal Squamous Cell Carcinoma Through Modulation of p53-Independent Cell-Cycle RegulationAkimitsu Iizuka, Mitsuro Kanda, Yusuke Sato, et al.
Annals of Surgical Oncology|January 20, 2024
Absence of Hypercoagulation Status after Neoadjuvant Treatment is Associated with Favorable Prognosis in Patients Undergoing Subtotal Esophagectomy for Esophageal Squamous Cell CarcinomaFumitake Sugiyama, Mitsuro Kanda, Dai Shimizu, et al.
Annals of Surgical Oncology|May 8, 2024
Therapeutic Potential of Antibody Targeting Neuronal Pentraxin Receptor in Esophageal Squamous Cell CarcinomaTakahiro Shinozuka, Mitsuro Kanda, Yusuke Sato, et al.
World Journal of Surgery|December 14, 2004
Treatment and risk factors for recurrence after curative resection of gastrointestinal stromal tumors of the stomachYoshinari Mochizuki, Yasuhiro Kodera, Seiji Ito, et al.
BMC Cancer|July 25, 2012
A randomized phase II trial to elucidate the efficacy of capecitabine plus cisplatin (XP) and S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment vs. SP randomized PII trial (XParTS II)Akira Tsuburaya, Satoshi Morita, Yasuhiro Kodera, et al.
Pageof 66